Loading
A phase 3 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Corporation, active and no longer recruiting.
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) is a phase 3 interventional study registered as NCT05429268 by Incyte Corporation, with 82 participants enrolled, started 2022-12-23 and due to reach its primary completion in 2026-03-30. Interventions recorded: Tafasitamab, Lenalidomide. Conditions listed: Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies.
Shares Tafasitamab, Lenalidomide, Monoclonal antibodies, Diffuse large B-cell lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/